Short answer
West Pharmaceutical Services (WST) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $875M (up 8.7% year over year) with net income of $214M.
Q3 2026 key financials · XBRL
- Revenue
- $875M
- +8.7% YoY · +0.3% QoQ
- Net income
- $214M
- +52.9% YoY · +39.0% QoQ
- Operating margin
- 30.6%
- Gross margin
- 39.7%
- EPS (diluted)
- $3.02
- +57.3% YoY · +40.5% QoQ
Source: XBRL data from the West Pharmaceutical Services (WST) Q3 2026 10-Q on SEC EDGAR. USD.
West Pharmaceutical Services Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $874.5M, up 8.7% YoY from $804.6M
- Consolidated gross margin 39.7% vs 36.6%; operating margin 30.6% vs 20.8%
- Best segment Proprietary Products: sales $728.8M, up 12.6%; worst West Vantage: $145.7M, down 7.3%
- Operating cash flow $403.4M vs $503.7M; share repurchases $685.3M
- Cash $464.1M vs $791.3M; headwinds from cyber-incident downtime, inflation and contract expiration
Risk Factors
- New cybersecurity risk triggered by May 2026 attack, involving data exfiltration and global system encryption
- Operational disruption from attack, requiring systems taken offline globally before full recovery
- Regulatory exposure from compromised personal information, including potential fines and reputational damage
- Financial risk from cybersecurity costs exceeding insurance policy limits
- Evolving AI-enabled attack techniques increasing unauthorized-access risk
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other West Pharmaceutical Services quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.